WO2014170842A3 - Substituted alkyl carboxylic acid derivatives as gpr agonists - Google Patents

Substituted alkyl carboxylic acid derivatives as gpr agonists Download PDF

Info

Publication number
WO2014170842A3
WO2014170842A3 PCT/IB2014/060763 IB2014060763W WO2014170842A3 WO 2014170842 A3 WO2014170842 A3 WO 2014170842A3 IB 2014060763 W IB2014060763 W IB 2014060763W WO 2014170842 A3 WO2014170842 A3 WO 2014170842A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
substituted alkyl
acid derivatives
alkyl carboxylic
agonists
Prior art date
Application number
PCT/IB2014/060763
Other languages
French (fr)
Other versions
WO2014170842A2 (en
Inventor
Rajiv Sharma
Somnath HALDER
Sanjay Kumar
Original Assignee
Piramal Enterprises Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Limited filed Critical Piramal Enterprises Limited
Publication of WO2014170842A2 publication Critical patent/WO2014170842A2/en
Publication of WO2014170842A3 publication Critical patent/WO2014170842A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to substituted alkyl carboxylic acid derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions.
PCT/IB2014/060763 2013-04-17 2014-04-16 Substituted alkyl carboxylic acid derivatives as gpr agonists WO2014170842A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812784P 2013-04-17 2013-04-17
US61/812,784 2013-04-17

Publications (2)

Publication Number Publication Date
WO2014170842A2 WO2014170842A2 (en) 2014-10-23
WO2014170842A3 true WO2014170842A3 (en) 2015-02-19

Family

ID=50685997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060763 WO2014170842A2 (en) 2013-04-17 2014-04-16 Substituted alkyl carboxylic acid derivatives as gpr agonists

Country Status (3)

Country Link
AR (1) AR096041A1 (en)
TW (1) TW201534593A (en)
WO (1) WO2014170842A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566267A (en) * 2016-01-27 2016-05-11 中国药科大学 Novel oxime ether derivative and preparation method thereof and application of derivative by serving as drug
MX2020008404A (en) 2018-02-13 2020-09-25 Gilead Sciences Inc Pd-1/pd-l1 inhibitors.
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7158577B2 (en) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド PD-1/PD-L1 inhibitor
KR20220150270A (en) 2019-10-07 2022-11-10 칼리오페, 인크. GPR119 agonists
EP4153589A1 (en) 2020-05-19 2023-03-29 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2011515341A (en) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド Conformationally restricted carboxylic acid derivatives useful for the treatment of metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
KR20120022801A (en) 2009-04-22 2012-03-12 아스텔라스세이야쿠 가부시키가이샤 Carboxylic acid compound
WO2012011125A1 (en) 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds

Also Published As

Publication number Publication date
AR096041A1 (en) 2015-12-02
WO2014170842A2 (en) 2014-10-23
TW201534593A (en) 2015-09-16

Similar Documents

Publication Publication Date Title
WO2014170842A3 (en) Substituted alkyl carboxylic acid derivatives as gpr agonists
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
EA201501122A1 (en) NEW AGONISTS OF SOMATOSTATIN RECEPTORS OF SUB-TYPE 4 (SSTR4)
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
JO3781B1 (en) Quinolone derivatives
MX2015017861A (en) Benzothiophene derivatives as estrogen receptor inhibitors.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
PH12016500885A1 (en) Novel heterocyclic compounds
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
TN2014000112A1 (en) Ep1 receptor ligands
MX2013002948A (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
CY1120744T1 (en) AZAINDOLIS ACETIC ACID PRODUCERS AND THE USE OF THESE AS REGULATORY PROSTAGLANDIN RECEPTORS D2
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
EA201790522A1 (en) SALT OF DERIVATIVE CEFALOSPORIN, ITS CRYSTAL SOLID MATTER AND METHOD OF ITS PREPARATION
MX2016011900A (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
MX351994B (en) Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5 -carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl]-amide.
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
EA201590452A1 (en) SALT COMPOUNDS OF BENZOTHIAZOLONE AS AGONISTS OF β-2-ADRENORECEPTORS
RS20150238A1 (en) Derivatives of (s)-2-amino-3-cyclohexyl-propionic acid, their preparation and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14722771

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14722771

Country of ref document: EP

Kind code of ref document: A2